Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane™ in Canada and Other

 Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for
 Exclusive Rights to Zertane™ in Canada and Other Territories to Broaden its
                           International Footprint

PR Newswire

GREENWOOD VILLAGE, Colo., April 10, 2014

GREENWOOD VILLAGE, Colo., April 10, 2014 /PRNewswire/ -- Ampio Pharmaceuticals
Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix
Pharmaceuticals, a specialty pharmaceutical company focused on developing and
commercializing late-stage prescription pharmaceuticals to improve men's
sexual health, has signed an agreement with Paladin Labs Inc., a leading
Canadian specialty pharmaceutical company, to provide exclusive rights to
market, sell and distribute Zertane™ in Canada, the Republic of South Africa,
Sub-Saharan Africa and Latin America.

Ampio Pharmaceuticals Logo

"We are pleased to have Paladin as our first North American partner to
commercialize Zertane. Our agreement with Paladin is consistent with Vyrix's
global commercialization strategy focused on developing partnerships with
established companies that are dominant in key international markets and have
a specialty that aligns with Zertane to maximize its visibility," said Jarrett
Disbrow, President and Chief Executive Officer of Vyrix Pharmaceuticals.

Disbrow continued, "This agreement further broadens the international
footprint for Zertane by adding Canada, Africa and Latin America to our
existing partnerships in South Korea and Brazil where the pending Australian
TGA approval of Zertane should enable product registration in the near-term.
We continue ongoing discussions with additional potential partners, which we
believe will position Zertane to gain maximum international exposure and drive
more value than aligning with a single worldwide partner."

Zertane (tramadol HCl) is an oral drug in late-stage development as a
proprietary treatment for premature ejaculation, a condition that has a major
impact on the quality of life for men and their sexual partners and has
demonstrated a favorable efficacy profile in clinical trials. We believe the
active ingredient in Zertane has multiple mechanisms of actions that can delay
ejaculation. These pharmaceutical qualities, favorable safety profile, and a
distinctive non-standard dosage not available in generic form, differentiate
Zertane from other treatments for premature ejaculation. Zertane is to be
taken 1-2 hours before sexual activity as needed and is not required to be
taken on a daily basis. There has not yet been an oral drug approved in the
U.S. for the treatment of premature ejaculation.

The agreement provides for an upfront payment, approval and revenue-based
milestone payments and an ongoing double-digit royalty stream to Vyrix.
Paladin and Vyrix will collaborate to apply for Health Canada approval for
Zertane to enable near-term registration in Canada with registrations in other
countries in the Territory to follow.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company
primarily focused on the development of therapies to treat prevalent
inflammatory conditions for which there are limited treatment options. We are
developing compounds that decrease inflammation by (i) inhibiting specific
pro-inflammatory compounds by affecting specific pathways at the protein
expression and at the transcription level; (ii) activating specific
phosphatase or depletion of the available phosphate needed for the
inflammation process; and (iii) decreasing vascular permeability. 

About Vyrix Pharmaceuticals
Vyrix Pharmaceuticals was created as a wholly-owned subsidiary of Ampio
Pharmaceuticals in order to maximize the clinical and commercial potential of
its late-stage sexual dysfunction products. Vyrix is currently focused on
advancing the development of Zertane™ for Premature Ejaculation (PE) in the US
and around the world.

About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing innovative
pharmaceutical products for the Canadian and emerging markets. Paladin has a
focused marketing and sales organization that has helped it evolve into one of
Canada's leading specialty pharmaceutical companies. Paladin is an operating
company of Endo International plc (NASDAQ: ENDP) (TSX: ENL), a global
specialty healthcare company focused on improving patients' lives while
creating shareholder value. Learn more at

Forward Looking Statement
Ampio's statements in this press release that are not historical fact and that
relate to future plans or events are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by use of words such as
"believe," "expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include risks associated with clinical trials,
expected results, regulatory approvals, including the ability of Vyrix to
obtain regulatory approval of Vyrix, and changes in business conditions and
similar events. The risks and uncertainties involved include those detailed
from time to time in Ampio's filings with the Securities and Exchange
Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q.

Logo -

Investor Contact:      Media Contact:
David Burke            Aaron Estrada
The Ruth Group         The Ruth Group
(646) 536 -7009        (646) 536 -7028

SOURCE Ampio Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.